• Citer

Analysis of HER2 expression and gene amplification in adenocarcinoma of the stomach and the gastro-oesophageal junction: rationale for the Belgian way of working.

par Jouret-Mourin, A;Hoorens, Anne;De Hertogh, Gert;Vanderveken, J;Demetter, Pieter ;Van Cutsem, Eric
Référence Acta gastro-enterologica Belgica (Ed. multilingue), 75, 1, page (9-13)
Publication Publié, 2012-03

Article révisé par les pairs

• Détails
• Contenu

Résumé :

The Human Epidermal growth factor Receptor 2 (HER2) has been established as a key player in the development of certain human tumors. ToGA trial has demonstrated that the addition of the monoclonal antibody blocking HER2 receptor, trastuzumab (Herceptin®), to chemotherapy significantly improves overall survival of patients with HER2-positive advanced or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. Therefore, it is essential that pathologists guarantee an accurate testing of HER2 status in these tumours. Following the international recommendations and the Belgian criteria for reimbursement of trastuzumab, a consortium of expert pathologists (Belgian Working Group Molecular Pathology) proposes an adaptation of the international guidelines in order to develop strategies for optimal performance, interpretation and reporting assays.